SCHEMBL6328735

SCHEMBL6328735

Cc1ccc(Nc2cccc(O)c2)c(C)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 2/20 0.67
CYP3A4 P08684 2/20 0.52
TSHR P16473 1/20 0.52
ACHE P22303 1/20 0.48
BRAF P15056 4/20 0.47
HDAC6 Q9UBN7 1/20 0.47
SYK P43405 1/20 0.47
MAPT P10636 3/20 0.46
GAA P10253 3/20 0.46
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 2/20 0.45
ALOX15 P16050 2/20 0.45
KMT2A Q03164 2/20 0.45
HSD17B10 Q99714 2/20 0.45
USP2 O75604 1/20 0.45
APP P05067 1/20 0.45
CYP1A2 P05177 1/20 0.45
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7001007 0.86 RAPGEF4 (0.53) RAPGEF4ACHEMAPTGAAALDH1A1
SCHEMBL5608725 0.85 NPSR1 (0.59) RAPGEF4CYP3A4MAPTGAAMEN1
SCHEMBL11536805 0.83 RAPGEF4 (0.54) RAPGEF4CYP3A4TSHRACHEBRAF
SCHEMBL3234606 0.82 RAPGEF4 (0.61) RAPGEF4CYP3A4TSHRBRAFHDAC6
Formaldehyde SCHEMBL9774242 0.82 CXCR2 (0.58) RAPGEF4CYP3A4TSHRACHEBRAF
SCHEMBL11563580 0.80 RAPGEF4 (0.55) RAPGEF4CYP3A4TSHRACHEMAPT
SCHEMBL11536888 0.80 RAPGEF4 (0.54) RAPGEF4CYP3A4TSHRACHEBRAF
SCHEMBL429859 0.80 GAA (0.62) RAPGEF4MAPTGAAMEN1KMT2A
SCHEMBL29473561 0.80 GAA (0.62) RAPGEF4MAPTGAAMEN1KMT2A
SCHEMBL7003942 0.80 RAPGEF4 (0.64) RAPGEF4MAPTGAAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919357-B2 α adrenergic agents MOLECULAR DESIGN INTERNATIONAL INC. (US) 2005-07-19 US disclosed
EP-1418907-A4 NOVEL ALPHA ADRENERGIC AGENTS MOLECULAR DESIGN INTERNAT INC (US) 2004-10-20 EP disclosed
EP-1418907-A1 NOVEL ALPHA ADRENERGIC AGENTS Molecular Design International Inc. (US) 2004-05-19 EP disclosed
US-20030092741-A1 Novel alpha adrenergic agents MOLECTULAR DESIGN INTERNATIONAL INC. 2003-05-15 US disclosed
WO-2003013515-A1 NOVEL ALPHA ADRENERGIC AGENTS MOLECTULAR DESIGN INTERNATIONAL INC. (US) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092741-A1 Novel alpha adrenergic agents ADRA1D, ADRB1, ADRA1B RAPGEF4 2602/4885CYP3A4 1191/4885TSHR 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.